{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:19:43Z","timestamp":1760833183842,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.nmd.2016.02.006","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T03:38:54Z","timestamp":1455593934000},"page":"309-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution"],"prefix":"10.1016","volume":"26","author":[{"given":"Jasem Y.","family":"Al-Hashel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail Ibrahim","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.nmd.2016.02.006_bib0010","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nmd.2016.02.006_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1176\/appi.ajp.163.3.521","article-title":"Association of schizophrenia and autoimmune diseases: linkage of Danish national registers","volume":"163","author":"Eaton","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.nmd.2016.02.006_bib0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0032-1329200","article-title":"Myasthenia gravis","volume":"32","author":"Silvestri","year":"2012","journal-title":"Semin Neurol"},{"key":"10.1016\/j.nmd.2016.02.006_bib0025","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0028-3908(02)00018-7","article-title":"Effects of atypical antipsychotics on vertebrate neuromuscular transmission","volume":"42","author":"Nguyen","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nmd.2016.02.006_bib0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archinte.1997.00440250045006","article-title":"Drugs and myasthenia gravis. An update","volume":"157","author":"Wittbrodt","year":"1997","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.nmd.2016.02.006_bib0035","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1176\/jnp.23.2.jnpe36","article-title":"Myasthenic crisis may mimic antipsychotic induced extrapyramidal syndromes","volume":"23","author":"Chiu","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.nmd.2016.02.006_bib0040","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.nmd.2016.02.006_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00325481.2000.11445249","article-title":"Drugs that can worsen myasthenia gravis","volume":"108","author":"Karcic","year":"2000","journal-title":"Postgrad Med"},{"key":"10.1016\/j.nmd.2016.02.006_bib0050","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archneur.1963.00460030070006","article-title":"Chlorpromazine-induced weakness in myasthenia gravis","volume":"8","author":"McQuillen","year":"1963","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2016.02.006_bib0055","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/j.1875-9114.1997.tb03085.x","article-title":"Drug-induced neuromuscular blockade and myasthenia gravis","volume":"17","author":"Barrons","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nmd.2016.02.006_bib0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-8993(79)90018-0","article-title":"The action of chlorpromazine at an isolated cholinergic synapse","volume":"164","author":"Argov","year":"1979","journal-title":"Brain Res"},{"issue":"1\u20133","key":"10.1016\/j.nmd.2016.02.006_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2006.07.011","article-title":"A model of anticholinergic activity of atypical antipsychotic medications","volume":"88","author":"Chew","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.nmd.2016.02.006_bib0070","series-title":"Stahl's essential psychopharmacology: neuroscientific basis and practical applications","first-page":"315","author":"Stahl","year":"2008"},{"year":"2011","series-title":"[package insert]","author":"Risperdal Consta","key":"10.1016\/j.nmd.2016.02.006_bib0075"},{"key":"10.1016\/j.nmd.2016.02.006_bib0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.nmd.2016.02.006_bib0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004714-200208000-00014","article-title":"Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction","volume":"22","author":"Spina","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"10.1016\/j.nmd.2016.02.006_bib0090","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.clinthera.2004.12.009","article-title":"Clinical review of a long-acting, injectable formulation of risperidone","volume":"26","author":"Knox","year":"2004","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.nmd.2016.02.006_bib0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pnp.264","article-title":"Myasthenia gravis unmasked by antipsychotic medication","volume":"17","author":"Wilson","year":"2013","journal-title":"Prog Neurol Psychiatry"},{"key":"10.1016\/j.nmd.2016.02.006_bib0100","first-page":"242","article-title":"Myasthenia in a patient with sarcoidosis and schizophrenia","volume":"57","author":"R\u00f3zsa","year":"2004","journal-title":"Ideggyogy Sz"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:04:11Z","timestamp":1760774651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896616000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":19,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0960896616000298"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2016.02.006","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2016.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}